This HTML5 document contains 49 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n7http://linked.opendata.cz/resource/drugbank/drug/DB06267/identifier/wikipedia/
n9http://linked.opendata.cz/resource/drugbank/drug/DB06267/identifier/pharmgkb/
n11http://linked.opendata.cz/resource/drugbank/drug/DB06267/identifier/pubchem-compound/
n18http://bio2rdf.org/drugbank:
n15http://linked.opendata.cz/resource/drugbank/drug/DB06267/identifier/pubchem-substance/
n8http://linked.opendata.cz/resource/drugbank/drug/DB06267/identifier/kegg-drug/
admshttp://www.w3.org/ns/adms#
n10http://linked.opendata.cz/resource/drugbank/drug/DB06267/identifier/drugbank/
n17http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n12http://linked.opendata.cz/resource/drugbank/drug/DB06267/identifier/chemspider/
xsdhhttp://www.w3.org/2001/XMLSchema#
n14http://linked.opendata.cz/resource/atc/
n13http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB06267
rdf:type
n3:Drug
n3:description
Udenafil is a new phosphodiesterase type 5 (PDE5) inhibitor used to treat erectile dysfunction (ED). It has been approved in South Korea and will be marketed under the brand name Zydena. It is not yet approved for use in the U.S., E.U., or Canada.
n3:generalReferences
# Ji HY, Shim HJ, Yoo M, Park ES, Lee HS: Transport of a new erectogenic udenafil in Caco-2 cells. Arch Pharm Res. 2007 Sep;30(9):1168-73. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17958337 # Ku HY, Ahn HJ, Seo KA, Kim H, Oh M, Bae SK, Shin JG, Shon JH, Liu KH: The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil. Drug Metab Dispos. 2008 Jun;36(6):986-90. Epub 2008 Feb 28. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18308836
n3:group
approved investigational
n3:indication
Investigated for use/treatment in erectile dysfunction and hypertension.
owl:sameAs
n17:DB06267 n18:DB06267
dcterms:title
Udenafil
adms:identifier
n7:Udenafil n8:D10027 n9:PA164776753 n10:DB06267 n11:6918523 n12:5293720 n15:99443240
n3:mechanismOfAction
Udenafil inhibits the cGMP specific phosphodiesterase type 5 (PDE5) which is responsible for degradation of cGMP in the corpus cavernosum located around the penis. Penile erection during sexual stimulation is caused by increased penile blood flow resulting from the relaxation of penile arteries and corpus cavernosal smooth muscle. This response is mediated by the release of nitric oxide (NO) from nerve terminals and endothelial cells, which stimulates the synthesis of cGMP in smooth muscle cells. Cyclic GMP causes smooth muscle relaxation and increased blood flow into the corpus cavernosum. The inhibition of phosphodiesterase type 5 (PDE5) by udenafil enhances erectile function by increasing the amount of cGMP.
n3:synonym
Udenafil DA-8159
n3:synthesisReference
Chan-Ho Lee, Chang-Yong Shin, Seul-Min Choi, Kyung-Koo Kang, Dong-Seong Kim, Byoung-Ok Ahn, Moo-Hi Yoo, "ACID ADDITION SALT OF UDENAFIL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME." U.S. Patent US20110306762, issued December 15, 2011.
n3:IUPAC-Name
n4:271B4B67-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4B6D-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4B6C-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4B69-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4B6A-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4B6B-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4B65-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4B63-363D-11E5-9242-09173F13E4C5 n4:271B4B66-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4B64-363D-11E5-9242-09173F13E4C5
n13:hasATCCode
n14:G04BE11
n3:H-Bond-Acceptor-Count
n4:271B4B73-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4B74-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4B6E-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4B6F-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4B71-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4B70-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4B72-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
268203-93-6
n3:Bioavailability
n4:271B4B79-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4B7B-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4B7C-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4B78-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4B77-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4B7A-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4B68-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4B75-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4B76-363D-11E5-9242-09173F13E4C5